Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence

Cancer Research

Volumn 60, Issue 8, 2000, Pages 2253-2257

  Hoon, Dave S B ^a   Bostick, Peter ^a   Kuo, Christine ^a   Okamoto, Tetsuro ^a   Wang, He Jing ^a,b   Elashoff, Robert ^a,b   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; TREATMENT INDICATION;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034655139     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Stadelmann, W. K., Rapaport, D. P., Soong, S. J., Reintgen, D. S., Buzaid, A., and Balch, C. Prognostic clinical and pathologic features. In: C. M. Balch, A. N. Houghton, A. J. Sober, and S-J. Soong (eds.), Cutaneous Melanoma, 3rd Ed., pp. 11-35. St. Louis, MO: Quality Medical Publishing, Inc., 1998.
2. Morton, D. L., Essner, R., Kirkwood, J. M., and Parker, R. G. Malignant melanoma. In: J. F. Holland, E. Frei III, D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, pp. 2467-2499. Baltimore, MD: Williams & Wilkins, 1998.
3. Hoon, D. S. B., Okamoto, T., Wang, H-J., Elashoff, R., Nizze, A. J., Foshag, L. J., Gammon, G., and Morton, D. L. Survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to HLA phenotype of patients. J. Clin. Oncol., 16: 1430-1437, 1998.
4. Morton, D. L., and Barth, A. Vaccine therapy for malignant melanoma. CA Cancer J. Clin., 46: 225-244, 1996.
5. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J. Clin. Oncol., 14: 7-17, 1996.
6. O'Day, S. J., Gammon, G., Boasberg, P. D., Martin, M. A., Kristedja, T. S., Guo, M., Stern, S., Edwards, S., Fournier, P., Weisberg, M., Cannon, M., Fawzy, N. W., Johnson, T., Essner, R., Foshag, L. R., and Morton, D. L. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony stimulating factor and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol., 17: 2752-2761, 1999.
7. Hoon, D. S. B., Wang, Y., Dale, P. S., Conrad, A. J., Schmid, P., Garrison, D., Kuo, C., Foshag, L. J., Nizze, A. J., and Morton, D. L. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol., 13: 2109-2116, 1995.
8. Kuo, C. T., Bostick, P. J., Irie, R. F., Morton, D. L., Conrad, A. J., and Hoon, D. S. B. Assessment of mRNA of β-1,4-N-acetylgalactosaminyltransferase as molecular marker for metastatic melanoma. Clin. Cancer Res., 4: 411-418, 1998.
9. O'Connell, C. D., Juhasz, A., Reeder, D. J., Hoch, R., and Hoon, D. S. B. Detection of tyrosinase mRNA in melanoma by QPCR. Clin. Chem., 44: 1161-1169, 1998.
10. Brossart, P., Keilholz, U., Willhauck, M., Scheibebogan, C., Mohler, T., and Hunstein, N. Hematogenous spread of malignant melanoma cells in different stages of disease. J. Investig. Dermatol., 101: 887-889, 1993.
11. Mellado, B., Colomer, D., Castel, T., Munoz, M., Carballo, E., Galan, M., Mascaro, J. M., Vives-Corrons, J. L., Grau, J. J., and Estape, J. Detection of circulating neoplastic cell by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J. Clin. Oncol., 14: 2091-2097, 1996.
12. Smith, B., Selby, P., Southgate, J., Pittman, K., Bradley, C., and Blair, G. E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet, 338: 1227-1229, 1991.
13. Palmieri, G., Strazzullo, M., Ascierto, P. A., Satriano, S. M. R., Daponte, A., Castello, G., and Melanoma Cooperative Group. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. J. Clin. Oncol., 17: 304-311, 1999.
14. Jung, F. A., Buzaid, A. C., Ross, M. I., Woods, K. V., Lee, J., Albitar, M., and Grimm, E. A. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J. Clin. Oncol., 15: 2826-2831, 1997.
15. Rose, T. M., Plowman, G. D., and Teplow, D. B. Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc. Natl. Acad. Sci. USA, 83: 1261-1265, 1986.
16. Lehmann, J. M., Riethmuller, G., and Johnson, J. P. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. USA, 86: 9891-9895, 1989.
17. Sarantou, T., Chi, D. D. J., Garrison, D. A., Conrad, A. J., Schmid, P., Morton, D. L., and Hoon, D. S. B. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res., 57: 1371-1376, 1997.
18. Klein, J. P., and Moeschberger, M. L. Log rank test: hypothesis testing. Survival Analysis, Techniques for Censored and Truncated Data, pp. 187-228. New York: Springer, 1997.
19. Klein, J. P., and Moeschberger, M. L. Cox regression: semiparametric proportional hazards regression with fixed covariates. Survival Analysis. Techniques for Censored and Truncated Data, pp. 229-268. New York: Springer, 1997.
20. Bostick, P., Chatergee, S., Chi, D., Huynh, K., Giuliano, A., Cote, R., and Hoon, D. S. B. Limitations of RT-PCR in the detection of micrometastases in the lymph nodes of breast cancer patients J. Clin. Oncol., 16: 2632-2640, 1998.
21. Kunter, U., Buer, J., Probst, M., Duensing, S., Dallmann, I., Grosse, J., Kirchner, H., Schluepen, E. M., Volkenandt, M., Ganser, A., and Atzpodien, J. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J. Natl. Cancer Inst., 88: 590-594, 1996.
22. Radinsky, R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev., 14: 323-338, 1995.
23. Glaser, R., Rass, K. Seiter, S., Hauschild, A., Christophers, E., and Tilgen, W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J. Clin. Oncol., 15: 2818-2825, 1997.
24. Reinhold, U., Ludtke-Handjery, H. C., Schnautz, S., Kreysel, H. W., and Abken, H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J. Investig. Dermatol., 108: 166-169, 1997.
25. Farthmann, B., Eberle, J., Krasagakis, K., Gstottner, M., Wang, N., Bisson, S., and Orfanos, C. E. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J. Investig. Dermatol., 110: 263-267, 1998.
26. Barth, A., Wanck, L. A., and Morton, D. L. Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg., 181: 193-201, 1995.
27. Bostick, P. J., Morton, D. L., Turner, R. R., Huynh, K. T., Wang, H-J., Elashoff, R., Essner, R., and Hoon, D. S. B. Prognostic significance of occult metastasis detected by sentinel lymphadenectomy and RT-PCR in early stage melanoma patients. J. Clin. Oncol., 17: 3238-3244, 1999.
28. Fujiwara, Y., Chi, D. J., Wang, H-J., Kelemen, P., Morton, D. L., Turner, R., and Hoon, D. S. B. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res., 1567-1571, 1999.
29. Huang, S. K. S., Okamoto, T., Morton, D. L., and Hoon, D. S. B. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J. Investig. Dermatol., 111, 662-667, 1998.
30. Fidler, I. J. Critical determinants of melanoma metastasis. J. Investig. Dermatol., IS: 203-208, 1996.
31. Mellado, B., Gutierrez, L., Castel, T., Colomer, D., Fontanillas, M., Castro, J., and Estape, J. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase reaction in long-term clinically disease-free melanoma patients. Clin. Cancer Res., 5: 1843-1848, 1999.
32. Pantel, K., Cote, R. J., and Fodstad, O. Detection and clinical importance of micrometastatic disease. J. Natl. Cancer Inst., 91: 1113-1124, 1999.